EXHIBIT 2.2
CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.
ASTERISKS DENOTE SUCH OMISSIONS.
FINISHED PRODUCT SUPPLY AGREEMENT
THIS FINISHED PRODUCT SUPPLY AGREEMENT, dated as of March 5, 2004 and
effective as of the Effective Date, is made and entered into by and between
Aventis Pharmaceuticals Inc., a company organized and existing under the laws of
the State of Delaware, and its Affiliates ("AVENTIS"), and Aeropharm Technology,
Inc., a company organized and existing under the laws of the State of Delaware
("PURCHASER"). Capitalized terms used in this Agreement shall have the meanings
ascribed to them in Article 1 hereof or as otherwise set forth herein.
RECITALS
WHEREAS, Aventis is engaged in the manufacture of a finished product
form of the compound Triamcinolone Acetonide in a chlorofluorocarbon ("CFC")
based propellant driven inhaler as sold in the United States under the
registered trademark Azmacort(R);
WHEREAS, this Agreement is being entered into in connection with
certain transactions in which Aventis and its Affiliates are divesting and
licensing certain assets related to the Product to Kos Life Sciences, Inc., an
Affiliate of Purchaser, pursuant to a Product Acquisition Agreement dated as of
the date hereof (the "PRODUCT ACQUISITION AGREEMENT");
WHEREAS, Purchaser desires to have Aventis manufacture and supply it
with finished Product for sale and distribution in the Territory during the Term
in accordance with this Agreement; and
WHEREAS, Aventis agrees to manufacture and supply to Purchaser finished
Product for sale and distribution in the Territory upon the terms and subject to
the conditions provided herein.
NOW, THEREFORE, in consideration of the mutual covenants and agreements
set forth in this Agreement, and for other good and valuable consideration, the
receipt of which are hereby acknowledged, the parties hereto hereby agree as
follows:
1
ARTICLE 1
DEFINITIONS
The following terms shall have the meanings set forth below. Unless the
context indicates otherwise, the singular shall include the plural and the
plural shall include the singular.
1.1 "4.5 DATE" has the meaning set forth in Section 7.10.
1.2 "ACT" means the United States Federal Food, Drug and Cosmetic Act,
as amended.
1.3 "ACTUAL LOST SALES" means the product of (i) the number of days
between the first day of a Canister Shortage and the last day of the Payment
Term and (ii) the Average Daily Sales Quantity.
1.4 "ADDITIONAL AGREEMENTS" has the meaning set forth in Section 7.1.
1.5 "ADJUSTED GROSS MARGIN PER UNIT" means ****.
1.6 "AFFILIATE" means a person or entity that, directly or indirectly,
through one or more intermediates, controls, is controlled by, or is under
common control with the person or entity specified. For the purposes of this
definition, control shall mean the direct or indirect ownership of (i) in the
case of corporate entities, securities authorized to cast more than fifty
percent (50%) of the votes in any election for directors, or (ii) in the case of
non-corporate entities, more than fifty percent (50%) ownership interest with
the power to direct the management and policies of such non-corporate entity.
1.7 "AGREEMENT " means this Finished Product Supply Agreement and all
schedules and exhibits attached hereto.
1.8 "ALTERNATE SUPPLIER" has the meaning set forth in Section 2.10.
1.9 "AVENTIS FACILITY" has the meaning set forth in Section 2.4(b).
1.10 "AVERAGE DAILY SALES QUANTITY" means the quotient obtained by
dividing (i) the total quantity of Product sold in the twelve (12) month period
ending on the last day of the month immediately preceding the month in which a
Canister Shortage occurs by (ii) three hundred sixty-five (365).
1.11 "BUSINESS DAY" means a day other than Saturday, Sunday or any day
on which a commercial bank in New York, New York is authorized to close. Any
reference in this Agreement to "day" whether or not capitalized shall refer to a
calendar day, not a Business Day.
2
1.12 "CANISTER" means an Azmacort Unprinted Canister, Part #CA-2742B
included in the Components sold to Purchaser pursuant to Section 2.5 of the
Product Acquisition Agreement and as set forth in SCHEDULE 4.5.
1.13 "CANISTER SHORTAGE" means the cessation of supply of Product by
Aventis hereunder due to an exhaustion of the supply of Canisters and the
resulting complete depletion of all inventories of Product held by Purchaser, as
demonstrated by reasonable documentary evidence thereof provided by Purchaser to
Aventis; PROVIDED, HOWEVER, that a Canister Shortage shall be deemed not to have
occurred in the event Purchaser takes any action outside the ordinary course of
business to deplete its inventory of the Product.
1.14 "CFC" has the meaning set forth in the first recital.
1.15 "CFC EVENT" has the meaning set forth in Section 7.19.
1.16 "CGMP" means current Good Manufacturing Practices as promulgated
under the Act at 21 CFR (chapters 210 and 211), as the same may be amended or
re-enacted from time to time.
1.17 "COMPONENTS" shall mean the canisters, valves, actuators and other
components used in connection with the manufacture of the Product and as listed
on SCHEDULE 1.17 attached hereto.
1.18 "CONVERSION DATE" has the meaning set forth in Section 7.10
1.19 "DISCRETIONARY MANUFACTURING CHANGES" has the meaning set forth in
Section 2.7(b).
1.20 "EFFECTIVE DATE" means the Closing Date as defined in the Product
Acquisition Agreement.
1.21 "FDA" means the United States Food and Drug Administration or any
successor agency thereof.
1.22 "FORCE MAJEURE" has the meaning set forth in Section 10.3.
1.23 "INDEMNITEE" has the meaning set forth in Section 9.3(a).
1.24 "INDEMNITOR" has the meaning set forth in Section 9.3(a).
1.25 "INITIAL PRODUCT COSTS" has the meaning set forth in Section 3.1.
1.26 "LAWS" means all laws, statutes, rules, regulations, ordinances
and other pronouncements having the effect of law of the United States, any
3
foreign country, supranational entity or any domestic or foreign state,
province, county, city or other political subdivision of any Regulatory
Authority.
1.27 "LOSS THRESHOLD" means losses of Canisters equal to or greater
than ****, calculated over the period commencing on the Effective Date and
ending on the day immediately prior to a Canister Shortage, such calculation to
be made solely by taking into account the following factors: (i) normal process
loss, (ii) loss due to human error of Aventis personnel or its subcontractor,
(iii) loss due to Product rejected for failure to meet Specifications, (iv)
deemed losses pursuant to Section 6.1 in the event, and solely to the extent,
that a recall results from any cause or event as a result of the defective
manufacture, testing, storage or handling of the Product by Aventis or its
Affiliates or its subcontactor and (v) any loss or use of Canisters for
validation or other purposes pursuant to any Discretionary Manufacturing Change
requested by Aventis, even if such Discretionary Manufacturing Change is
consented to by Purchaser.
1.28 "METHOD TRANSFER" has the meaning set forth in Section 5.10.
1.29 "NDA" means a New Drug Application pursuant to Section 505 of the
Act (21 U.S.C. Section 355) submitted to the FDA or any successor application or
procedure or any foreign counterpart of a U.S. New Drug Application for approval
to market, including, where applicable, applications for pricing and
reimbursement approval.
1.30 "NEW COMPONENTS" means the new canisters and valves to be used in
connection with the manufacture of the Product and to be supplied by Purchaser
upon the exhaustion or expiration of, and as a replacement for, the Old
Components purchased by Purchaser on the Effective Date.
1.31 "OLD COMPONENTS" means Canisters and Valves DF10-50RC20 (OR
CEBIC), Part# VL-0456D, made with gaskets compounded from Zeosil and perbunan
rubber and stockpiled by Aventis as specified on SCHEDULE 4.5 hereof.
1.32 "PAYMENT TERM" means the period commencing on the Effective Date
and ending on the two (2) year anniversary thereof.
1.33 "PRIME RATE" has the meaning set forth in Section 3.2(a).
1.34 "PRODUCT" means the fully finished product forms (including
complete packaging of same) of the pharmaceutical product (Triamcinolone
Acetonide) in a CFC based propellant driven inhaler and more particularly
defined in NDA # 18-117.
1.35 "PRODUCT ACQUISITION AGREEMENT" has the meaning set forth in the
Recitals.
1.36 "PURCHASED COMPONENTS" has the meaning set forth in Section 4.5.
1.37 "RESOURCE LIMIT" has the meaning set forth in Section 5.10.
1.38 "REGULATORY APPROVAL" means the technical, medical and scientific
licenses, registrations, authorizations and approvals, including, without
4
limitation, approvals of NDA's, supplements and amendments, pre- and post-
approvals, pricing and third party reimbursement approvals, and labeling
approvals, of any Regulatory Authority necessary for the development, including
the conduct of clinical trials, manufacture, distribution, marketing, promotion,
offer for sale, use, import, export or sale of a Product in a regulatory
jurisdiction.
1.39 "REGULATORY AUTHORITY" means the FDA and any other national,
supra-national, regional, state or local regulatory agency, department, bureau,
commission, council or other governmental entity in each country in the
Territory.
1.40 "REPRESENTATIVES" has the meaning set forth in Section 8.1(b).
1.41 "REQUIRED MANUFACTURING CHANGES" has the meaning set forth in
Section 2.7(a).
1.42 "SPECIFICATIONS " means the written specifications for the Product
as set forth in applicable NDAs.
1.43 "SUPPLY COMMITTEE" has the meaning set forth in Section 7.13.
1.44 "TECHNICAL AGREEMENT " has the meaning set forth in Section 5.9
1.45 "TERM" has the meaning set forth in Section 4.1.
1.46 "TERRITORY" means worldwide.
1.47 "THIRD PARTY CLAIM" has the meaning set forth in Section 9.3(a).
1.48 "THIRD PARTY LIABILITIES" has the meaning set forth in Section
9.1.
1.49 "VALVE DATE" has the meaning set forth in Section 7.10.
Capitalized terms used but not defined herein shall have the meanings ascribed
to such terms in the Product Acquisition Agreement
ARTICLE 2
MANUFACTURE, PURCHASE AND SALE OF PRODUCT
2.1 SUPPLY. Pursuant to the terms and conditions of this Agreement,
Aventis agrees to supply Product exclusively to Purchaser in the Territory. So
long as Aventis or its permitted designee is willing and able, or is not
otherwise in material breach of this Agreement, Purchaser agrees to, and agrees
to cause its permitted designee to, purchase exclusively from Aventis or its
permitted designee, Purchaser's requirement of Product for purposes of
distribution by Purchaser in the Territory during the Term hereof. Subject to
5
its maximum monthly and annual manufacturing capacity for the Product (as set
forth in SCHEDULE 2.6(A)), Aventis agrees to provide manufacturing capacity
sufficient to fulfill Purchaser's requirements for the Product, which
requirements shall be reflected by Purchaser's forecasts as set out in this
Article 2.
2.2 FORECASTS.
(a) LONG-RANGE FORECASTS. Within ninety (90) days after the Effective
Date, and by July 1 of each calendar year thereafter during the Term, Purchaser
shall furnish Aventis with a quarterly forecast of the quantities of each
Product that Purchaser intends to order for the shorter of (i) the remaining
Term or (ii) three (3) years. Such forecasts shall represent the most current
estimates for planning purposes, but shall not be purchase commitments. Such
forecasts shall not exceed Aventis' maximum monthly and annual capacity as set
forth in Section 2.6(a), unless a forecast in excess of Aventis' maximum monthly
and annual capacity is mutually agreed to in writing by the parties.
(b) SHORT TERM ROLLING FORECASTS. In addition to the non-binding, long
range forecasts provided in Section 2.2(a), commencing with the first (1st)
Business Day of the month immediately succeeding the Effective Date, and on the
first (1st) Business Day of each month thereafter, Purchaser shall furnish
Aventis with a rolling forecast of the quantities of Product that Purchaser
intends to order by month during the twelve (12) month period (or such shorter
period as remains in the Term) commencing on the Effective Date. Such forecasts
shall be broken down into Product type, quantities and shipping dates.
Notwithstanding the foregoing, the Purchaser shall utilize Aventis' scheduled
firm orders for the first three (3) months of this Agreement, as specified on
SCHEDULE 2.2(B), and such orders shall constitute the first three (3) month
portion of Purchaser's initial twelve (12) month forecast; PROVIDED, HOWEVER
that the Purchaser shall not be required to purchase amounts for any one of
these first three (3) months that deviate by more than twenty-five percent (25%)
from the quantities set forth on SCHEDULE 2.2(B) for such month. Such forecasts
shall not exceed Aventis' maximum monthly and annual capacity limitations as set
forth in Section 2.6(a). Purchaser shall be required to purchase one hundred
percent (100%) of the amount of Products forecast for the first six (6) months
of each rolling forecast.
(c) If Aventis notifies Purchaser in writing within ten (10)
Business Days after Purchaser's delivery of a rolling forecast, Aventis shall be
entitled to reject that portion of the order in a rolling forecast, and require
Purchaser to submit a revised rolling forecast, if such rolling forecast fails
to meet the following parameters:
-------------------------------------- -------------------------------------------------------------
PERMISSIBLE INCREASE OR DECREASE OF PRODUCT
MONTH OF ANY GIVEN COMPARED TO THE QUANTITY SPECIFIED IN THE
ROLLING FORECAST ROLLING FORECAST DELIVERED THE PREVIOUS MONTH
-------------------------------------- -------------------------------------------------------------
-------------------------------------- -------------------------------------------------------------
Months 1 2, 3, 4 and 5 None
-------------------------------------- -------------------------------------------------------------
-------------------------------------- -------------------------------------------------------------
-------------------------------------- -------------------------------------------------------------
Months 6, 7 and 8 No less than 75% and no more than 125% of
Months 7, 8 and 9, collectively, of the previous
forecast.
-------------------------------------- -------------------------------------------------------------
-------------------------------------- -------------------------------------------------------------
Months 9, 10 and 11 No less than 50% and no more than 150% of Months 10, 11 and
12, collectively, of the previous forecast.
-------------------------------------- -------------------------------------------------------------
-------------------------------------- -------------------------------------------------------------
6
(d) In no event shall Aventis be required to supply orders in
excess of the maximum monthly or annual capacity as set forth in Section 2.6(a).
Aventis shall not be responsible or otherwise required to accept any purchase
order to the extent of an insufficient supply of New Components.
2.3 FIRM ORDERS.
(a) Purchaser shall place purchase orders with Aventis for
Products to be delivered for the first one hundred eighty (180) days of each
Rolling Forecast. All purchase orders must be received by Aventis at least six
(6) months prior to the delivery date specified in each respective order.
Purchaser acknowledges that Products are produced in full batch quantities. Such
orders shall be in full batch quantities and when combined with all other
purchase orders for the applicable six (6) month period are at least as great
and no greater than the amount required to be purchased by Purchaser pursuant to
Section 2.2(c) for each Product. In addition, the number of such purchase orders
shall not exceed one (1) per month for each Product, unless they are a greater
monthly number is agreed to by Aventis, and, to the extent possible, shall be
delivered to Aventis on or about the fifteenth (15th) of such month. Each
purchase order shall specify the delivery schedule within the month and Aventis
shall deliver against each such purchase order in accordance with Section 2.4.
Purchaser shall be obligated to purchase all such Products ordered and delivered
by the delivery date specified in Purchaser's purchase order, PROVIDED that such
Products meet the Specifications. Unless otherwise specified in writing by
Aventis, all orders placed by Purchaser with Aventis hereunder shall be
addressed as follows:
Aventis Pharmaceuticals Inc.
000 Xxx Xxxx Xxxx Xxxxx Norte Industrial
Manati, Puerto Rico 00674
Attn: Xxxxxxx Xxxxxxxxx, Supply Chain Leader
Mail: X.X. Xxx 000, Xxxxxx, X.X. 00000-0000
Fax: (000) 000-0000
Telephone: (000) 000-0000 / Ext. 1400
(b) Any purchase orders, purchase order releases,
confirmations, acceptances, advices and similar documents submitted by either
party in conducting the activities contemplated under this Agreement are for
administration purposes only and shall not add to or modify the terms of this
7
Agreement. To the extent of any conflict or inconsistency between this Agreement
and any such document, the terms and conditions of this Agreement shall control
as to a particular order unless otherwise agreed to in writing by the parties.
2.4 DELIVERY.
(a) Aventis shall meet the delivery dates and order quantities
indicated in Purchaser's binding and accepted firm orders for all Products. Any
shipment delivered that is within plus or minus seven and one half percent
(+/-7.5%) of the quantity ordered and/or plus or minus seven (+/-7) Business
Days of the delivery date specified on the relevant firm order will be
considered as delivered on time.
(b) Delivery terms for Product shall be EXW (Incoterms 2000)
Aventis' manufacturing facility, warehouse or such other facility mutually
agreed to by the parties (the "AVENTIS FACILITY"). Title and risk of loss shall
pass to Purchaser once the Product is placed on the loading dock of the Aventis
Facility. Purchaser shall be responsible for all freight, insurance, handling,
fees, taxes and other costs associated with the shipment of Product, as well as
all export licenses, import licenses and customs formalities for the import and
export of goods.
2.5 REJECTED GOODS/SHORTAGES.
(a) NOTICE; REPLACEMENT. Purchaser shall notify Aventis in
writing of (i) any claim relating to Product that fails to meet the
Specifications, or (ii) any shortage in quantity of any shipment of Product as
soon as reasonably practical, but not later than thirty (30) days (or sixty (60)
days in the event an outside testing laboratory approved by Purchaser is used)
of receipt of such Product (unless such failure to meet Specifications is due to
a latent or undetectable defect at such time). Purchaser shall be deemed to have
accepted the Product if it does not provide Aventis written notice of such
shortfall or failure to meet specification within such thirty (30) day period
(or sixty (60) day period in the event an outside testing laboratory approved by
Purchaser is used) (unless such failure to meet Specifications is due to a
latent or undetectable defect at such time). If the parties agree that such
Product is defective or that there is a shortage, Aventis shall replace the
defective Product or use its commercially reasonable efforts to make up the
shortage as soon as possible but in no event later than the next practical
delivery date, at no additional cost to Purchaser. Purchaser shall make
arrangements with Aventis for the return or disposal of any rejected Product;
the costs of such return or disposal shall be paid by Aventis. In the event that
only a limited supply of Product is available to replace or supply such
rejection or shortage, then Aventis shall ship to Purchaser such quantities of
Product as are available, supply the remaining amount due as soon as possible
thereafter or, reimburse or credit Purchaser against future orders, at
Purchaser's option, for amounts paid for the remaining quantity of rejected
Product.
(b) DISPUTES. If Aventis disagrees with Purchaser's claim that
such Product fails to meet the applicable Specifications, Aventis and Purchaser
representatives shall promptly attempt to resolve such dispute. If the
representatives cannot resolve such dispute within ten (10) Business Days of the
8
date Purchaser notifies Aventis of its determination that the Products failed to
meet the applicable Specification, a sample of such Product shall be submitted
by Aventis and Purchaser to a mutually agreed upon qualified laboratory for
testing against the Specifications and the test results obtained by such
laboratory shall be final and controlling. The fees and expenses of such
laboratory testing shall be borne entirely by the party whose Product analysis
was in error. In the event the test results indicate that the Product in
question does not conform to the Specifications, Aventis shall replace such
Product at no additional cost to Purchaser as soon as reasonably possible after
receipt of such results; PROVIDED, HOWEVER, Aventis shall have no liability to
Purchaser if Product fails to meet the Specifications if the Product: (i) has
been tampered with or otherwise altered once title has passed to Purchaser; (ii)
has been subject to misuse, negligence or accident once title has passed to
Purchaser, (iii) has been stored, handled or used by others in a manner contrary
to applicable regulatory requirements once title has been passed to Purchaser or
(iv) so fails, and such failure is attributable to a New Component (excluding,
however, failure arising from the handling or attachment of such New Component
by Aventis or its Affiliates).
(c) SOLE REMEDY. The provisions of (i) Sections 2.5(a) in the
case of shortage in quantity of any shipment of Product, (ii) except as
otherwise provided in Section 9.2(a) herein with respect to Third Party Claims,
Sections 2.5(a) and (b) in the case of Product that fails to meet the
Specifications and (iii) Section 2.12 in the case of a Canister Shortage, shall
be the sole remedies available to Purchaser with respect to any shortage in
quantity of any shipment of Product, Product that fails to meet the
Specifications, and/or Product lost in production, as the case may be.
2.6 CAPACITY.
(a) CAPACITY. Aventis' maximum monthly and annual capacity to
manufacture Product is set forth on SCHEDULE 2.6(A).
(b) AVENTIS NOTICE. In the event that Aventis, upon receiving
a forecast under Section 2.2(b) or a firm order under Section 2.3, is, or
anticipates that it will be, unable to meet such forecast or firm order, either
in whole or in part, due to any reason, Aventis shall give written notice of
such inability to Purchaser within five (5) Business Days of receipt of such
forecast or firm order (or upon Aventis' reasonable belief that it cannot
fulfill the forecast or firm order, if such date is after such five (5) Business
Day period). If such inability is partial, Aventis shall fulfill firm orders
with such quantities of Product as are available.
2.7 MANUFACTURING CHANGES.
(a) REQUIRED MANUFACTURING CHANGES. For changes to the
Specifications or manufacturing processes that are required by changes in
applicable Laws (collectively, "REQUIRED MANUFACTURING CHANGES"), Aventis and
Purchaser shall cooperate in making such changes and use commercially reasonable
efforts to implement such changes promptly.
(b) DISCRETIONARY MANUFACTURING CHANGES. For changes to the
Specifications or manufacturing process that are not Required Manufacturing
Changes (collectively, "DISCRETIONARY MANUFACTURING CHANGES"), Aventis and
Purchaser must each agree in writing to any Discretionary Manufacturing Changes
9
and shall, to the extent commercially reasonable under the circumstances,
cooperate fully in making such changes, and each agrees that it shall not
unreasonably withhold its consent to such Discretionary Manufacturing Changes.
Notwithstanding the foregoing, Aventis' standard change control procedures shall
be utilized in reviewing such changes.
(c) CANISTERS. Notwithstanding the provisions of this
subsection, Aventis shall not make any Discretionary Manufacturing Changes that
require the utilization of the Canisters without first obtaining Purchaser's
consent to such utilization.
(d) MANUFACTURING CHANGES. Notwithstanding the foregoing, all
internal and external costs, including, without limitation, obsolete raw
materials, regulatory filings, work-in-process, Product, packaging and labeling
materials (i) associated with Required Manufacturing Changes relating solely to
Product in the Territory shall be borne by Purchaser, and (ii) all costs
associated with Discretionary Manufacturing Changes shall be borne by the party
initiating such changes.
****
2.8 LABELING AND PACKAGING. Purchaser shall be responsible for all
costs of developing new packaging and labeling for the Product for use by
Purchaser after the date hereof, including without limitation obsolete inventory
of packaging and labeling materials (including any Aventis labeling and
packaging materials specified on SCHEDULE 2.8 hereof that are no longer used by
Purchaser following the Effective Date), and shall provide Aventis all art work
from vendors selected by Purchaser and pharmacological information, usage
instructions and warnings to be applied to each Product, which shall be
consistent with the FDA or Regulatory Authority approved labeling for the
Product. Purchaser shall provide such information pursuant to this Section 2.8
to Aventis in sufficient time in advance of delivery requirements for the
Product set forth in this Agreement.
10
2.9 APPOINTMENT OF SUBLICENSEES OR SUBCONTRACTORS. Subject to Section
2.7(e) and the provisions of the Technical Agreement pertaining to change
control, Aventis may elect to appoint an Affiliate or a third party as
sublicensee or subcontractor for the purpose of manufacturing, testing and
supplying Product; PROVIDED, however, that such Affiliate or third party is
subject to a written agreement that subjects such Affiliate or third party to
all relevant restrictions and limitations in this Agreement that pertain to
Aventis and Aventis remains responsible for the performance by such Affiliate or
third party. Notwithstanding the foregoing, Aventis shall not be permitted to
appoint a sublicensee or subcontractor without the consent of Purchaser (which
consent shall not be unreasonably withheld or delayed) if such appointment would
require Regulatory Approval.
****
2.11 SHELF-LIFE. Subject to any applicable Law or directive of any
Regulatory Authority, the remaining shelf life of the Products supplied by
Aventis to Purchaser shall be at least **** months (based on the
currently-approved **** month dating period) at the time of placement for pickup
by Purchaser on the loading dock of the Aventis Facility. In the event that, for
legal, regulatory or other reasons, the remaining shelf life of Products
supplied is less than **** months, Purchaser may elect, in its discretion, to
accept such Products notwithstanding such fact, and Purchaser hereby agrees to
discuss such situation with Aventis prior to making (or not making) such
election.
****
11
ARTICLE 3
PRICING AND PAYMENT
3.1 PRICING.
(a) The initial costs payable to Aventis by Purchaser for the
Product shall be as set forth on SCHEDULE 3.1 (together, the "INITIAL PRODUCT
COSTS"). The Initial Product Costs are based upon an annual volume of supply of
Product hereunder equal to **** (the "MINIMUM ANNUAL VOLUME"). On February 1,
2005, and on February 1 of each calendar year thereafter, Aventis shall
determine the volume of Products sold under this Agreement in the immediately
prior calendar year (which calculation shall be annualized for the calendar year
2004) and, to the extent such amount is less than the Minimum Annual Volume,
Aventis shall provide Purchaser a written notice (the "PRICE ADJUSTMENT NOTICE")
indicating the increased fixed cost of the Product as a result of not meeting
such Minimum Annual Volume. To the extent that the volume of Products sold
hereunder is less than the Minimum Annual Volume, Purchaser shall pay Aventis a
lump sum amount to compensate Aventis for the increased fixed cost of supply of
the Product, as reasonably determined by Aventis and as set forth in the Price
Adjustment Notice. Such payment shall be due and payable no later than ten days
following delivery by Aventis of the Price Adjustment Notice (unless Purchaser,
in good faith, is disputing such price adjustment).
(b) The Initial Product Costs will remain firm until December
31, 2004. Beginning on January 1, 2005 and on January 1 of each calendar year
thereafter, the Initial Product Cost shall be increased to reflect increases in
the Producer Price Index as published by the U.S. Department of Labor,
Pharmaceutical Preparations Series ID# 2834 (the "PPI") for the calendar year
prior to the year for which any such adjustment is to take place. In the event
that the PPI is not available until after January 1 of any given year, then upon
its availability the Initial Product Cost shall be retroactively adjusted in
accordance therewith and Purchaser shall be invoiced for the difference between
the amounts paid by the Purchaser for such year prior to such adjustment and the
Initial Product Cost as so adjusted.
(c) In addition to the foregoing adjustments, if Aventis'
documented aggregate material costs increase at any time in excess of the PPI
increase described in clause (b) above, then Aventis shall increase the Initial
Product Cost by an amount equal to such excess; PROVIDED, HOWEVER, that if the
Initial Product Cost is scheduled to increase by more than an aggregate **** for
any calendar year, Aventis shall notify Purchaser, and Aventis and Purchaser
shall consult with each other and take such actions as may be mutually agreed to
(including attempting to renegotiate the price increase of any individual raw
material item or component). Notwithstanding the foregoing, Aventis shall not be
responsible for any delay or other production or manufacturing issues as a
result of any actions requested, or suggestions made, by Purchaser.
(d) Notwithstanding anything to the contrary contained herein,
the sum of ****, once paid by Purchaser under the Product Acquisition Agreement
for the purchase of the Components shall be credited against the first **** to
otherwise be paid by Purchaser for the acquisition of Product hereunder.
12
3.2 PAYMENT.
(a) TERMS. All payments required by this Agreement shall be
made in United States Dollars by wire transfer to an account designated in
writing by Aventis. All invoices are to be paid in full without any setoff or
deduction except as permitted in this Agreement and payment must be received
within thirty (30) days from the date of receipt of invoice. The date of each
invoice shall be the date the Products are available for shipment pursuant to
Section 2.4. Payment shall be made without deduction, deferment, set-off, lien
or counterclaim of any nature, other than for rejected or returned goods for
which a credit acknowledgment has been issued by Aventis. Time for payment shall
be of the essence. Interest shall accrue on any amount overdue at the lesser of
(i) the annual prime rate as reported by the WALL STREET JOURNAL, New York
Edition, or any other reputable publication mutually agreed to in writing by the
parties (the "PRIME RATE") on the date such payment is due, plus an additional
**** or (ii) the maximum rate permitted by Law, such interest to begin accruing
on a daily basis from the date of invoice, and shall accrue both before and
after judgment; PROVIDED, HOWEVER, in the case of a good faith dispute regarding
payment resolved to be due and not paid within three (3) Business Days after
such resolution, such interest shall begin accruing on a daily basis from the
date such payment becomes overdue, and shall accrue both before and after
judgment; PROVIDED, FURTHER, in the case of a good faith dispute regarding
payment, Purchaser may in its discretion determine to pay such amounts disputed
to be overdue and in the event amounts are finally determined not to be due by
Purchaser, Aventis shall repay such excess amounts to Purchaser determined not
be due. The foregoing interest shall begin to accrue and be payable to Aventis
without notice.
(b) DEFAULT. With respect to defaults of payment not cured
within thirty (30) Business Days after receipt of written notice from Aventis to
Purchaser, Aventis shall, in its sole discretion, and without prejudice to any
other of its accrued rights, be entitled to suspend the provision of the Product
or to terminate this Agreement by notice in writing to Purchaser exercised at
any time thereafter until such default is cured; PROVIDED, HOWEVER, that a good
xxxxx xxxx fide dispute by Purchaser regarding a payment pursuant to this
Agreement shall not be considered a default of payment so long as Purchaser
notifies Aventis in writing of such dispute within the later of five (5)
Business Days from the date of receipt of invoice or the date of payment.
Purchaser acknowledges it will notify Aventis promptly upon a determination that
a dispute exists regarding a payment.
ARTICLE 4
TERM AND TERMINATION
4.1 TERM; SUPPLY OF PRODUCT. The Term will commence upon the Effective
Date and will continue for a five (5) year period thereafter, unless terminated
earlier in accordance with the provisions of Section 4.2 (the "TERM").
Notwithstanding the foregoing, this Agreement may be renewable upon the mutual
agreement of the parties, on mutually acceptable terms, which shall be
comparable to those contained herein.
13
4.2 EARLY TERMINATION. Either Purchaser or Aventis (or one of them as
may be indicated in the applicable provision) may terminate this Agreement by
notice in writing to the other party upon the occurrence of any of the following
events (and subject to such prior notice periods as may be indicated in the
applicable provision):
(a) if the other party commits a material breach of this
Agreement (other than a payment default, which shall be governed by the
provisions of Section 3.2(b)), which in the case of a breach capable of remedy
shall not have been remedied within thirty (30) days of the receipt by the other
party of a written notice identifying the breach and requiring its remedy or
such longer time as the party in breach may demonstrate to the other party is
necessary to remedy the breach using its reasonable efforts to do so;
(b) if the other party ceases for any reason to carry on
business, but not as the result of a merger, acquisition or reorganization with
one or more entities whether in a single transaction or a series of
transactions, or convenes a meeting of its creditors or has a receiver or
manager appointed in respect of all or substantially all of its assets or is the
subject of an application for an administration order or of any proposal for a
voluntary arrangement or enters into liquidation, whether compulsorily or
voluntarily or undergoes any analogous act or proceedings under foreign law;
(c) if any Law is enacted that would render it impossible for
the other party to perform its obligations hereunder;
****
(e) as permitted by Section 7.8;
****
****
Anything herein to the contrary notwithstanding, in the event that the Product
Acquisition Agreement is terminated prior to the Closing Date (as defined
therein), this Agreement shall automatically terminate and be of no further
force or effect.
4.3 CONSEQUENCES OF TERMINATION AND SURVIVAL. Termination of this
Agreement for whatever reason shall not affect the accrued rights and
obligations of either Aventis or Purchaser arising under or out of this
Agreement. The obligations under Article 6 (Product Recalls), Article 8
(Nondisclosure and Confidentiality), Article 9 (Limitation of Liability,
Indemnification and Insurance) and Article 10 (General Provisions), the
14
covenants, representations, warranties and warranty exclusions contained in
Article 7 (Representations Warranties and Covenants) and any other provision
which expressly or by implication is intended to survive expiration or
termination shall survive expiration or termination of this Agreement.
4.4 ACCRUED OBLIGATIONS. Upon the expiration or earlier termination of
this Agreement, Purchaser shall pay to Aventis: (i) all amounts outstanding and
remaining to be paid for Product supplied prior to such expiration or
termination; (ii) all binding amounts for Product firm orders forecasted
pursuant to Section 2.2 or ordered pursuant to Section 2.3 prior to the
expiration or termination; PROVIDED that Aventis delivers such Product in
accordance with the Specifications; and (iii) all amounts representing the
purchase by Aventis of Components or other raw materials in reliance upon
binding amounts of forecasts or firm orders pursuant to Section 2.2. or 2.3,
(iv) all amounts representing remaining inventory of Product and all Product
work in process undertaken in accordance with binding amounts of forecasts and
firm orders and (v) all stockpiled inventory of CFC and valves, notwithstanding
whether such inventory was ordered pursuant to binding forecasts.
4.5 ADDITIONAL OBLIGATIONS FOR PURCHASED COMPONENTS. Purchaser and
Aventis hereby acknowledge and agree that in accordance with the Product
Acquisition Agreement, Purchaser has purchased those Components listed on
SCHEDULE 4.5 (the "PURCHASED COMPONENTS"), and that Purchaser assumes all risks
associated with such Purchased Components due to obsolescence, dating or
otherwise. In addition, due to the fact that Purchaser will receive a credit
under this Agreement in an amount equal to the value of the Purchased
Components, Purchaser hereby agrees to promptly reimburse Aventis, upon receipt
of reasonable documentation evidencing the quantity of such remaining Purchased
Components, for the value of all such Purchased Components (at the prices set
forth on SCHEDULE 4.5) to the extent any such Purchased Components are no longer
used or cannot be used as a result of obsolescence or validation of New
Components or termination of this Agreement other than as a result of a breach
of this Agreement by Aventis.
4.6 ASSISTANCE AT TERMINATION. Upon expiration or the earlier
termination of this Agreement by Purchaser pursuant to Section 4.2 above,
Aventis shall transfer to Purchaser or its designee without cost to Purchaser,
all regulatory information and other information and materials necessary for
Purchaser or its designee to assume responsibility for performance of the
manufacturing activities undertaken by Aventis or the Alternate Supplier under
this Agreement, and the parties shall establish such operational procedures as
are reasonably necessary for Purchaser or its designee to assume such
responsibility. In connection with the foregoing, during the three (3) month
period following the expiration or termination of this Agreement, Purchaser
shall be permitted to consult with Aventis' technical personnel on the specified
manufacturing activities; PROVIDED, HOWEVER, that Aventis shall not be required
to spend more than a total of forty (40) hours consulting with Purchaser during
such three (3) month period. In addition, within the six (6) month period prior
to the termination of the Agreement, Purchaser and/or its designee shall be
permitted to send no more than five employees to Aventis' manufacturing
facilities to observe Aventis' performance of its manufacturing activities in
actual practice for periods of not more than fifteen (15) Business Days during
such six (6) month period. In no event shall Aventis be required to send any of
its personnel to Purchaser's or its designees' locations. Unless Aventis is in
material breach of this Agreement, Purchaser shall bear the reasonable costs and
15
expenses incurred by Aventis in connection with facilitating the transfer of any
manufacturing activities to Purchaser, including: (i) the internal cost of any
Aventis personnel providing any of the services required hereunder calculated on
the basis of Aventis' then current FTE rates; and (ii) cost of any samples or
materials provided by Aventis, together with any handling costs associated
therewith. For purposes of clarification, in no event shall Aventis be
responsible for the payment or performance of (i) demonstration or qualification
batches or (ii) laboratory services for performing stability testing, in-process
testing or other testing associated with demonstration or qualification batches
to support a technical transfer.
ARTICLE 5
CERTIFICATES, ACCESS AND REGULATORY MATTERS
5.1 TESTING; CERTIFICATE OF ANALYSIS. Aventis shall perform, or cause
to be performed all tests required to be performed by Aventis pursuant to the
Technical Agreement on each lot of Product manufactured pursuant to this
Agreement before delivery to Purchaser. Each test report shall set forth the
items tested, Specifications and test results in a certificate of analysis,
containing the types of information which shall have been approved by mutual
agreement of the parties, for each lot delivered. Aventis shall send, or cause
to be sent, such certificates to Purchaser simultaneously with delivery of each
lot unless otherwise agreed in writing by the parties.
5.2 NOTICE OF FAILURE TO MEET SPECIFICATIONS. Upon Aventis' discovery
that any batch or lot of Product fails to conform to the applicable
Specifications, Aventis will notify Purchaser within five (5) Business Days of
such failure to meet the applicable Specifications and of the nature thereof.
Aventis shall investigate all such failures promptly and cooperate with
Purchaser in determining the cause for the failure and a corrective action to
prevent future failures.
5.3 RECORDS. Aventis shall maintain all manufacturing, packaging,
analytical and stability records, all records of shipment, and all validation
data relating to the Product to the extent and for the time periods required by
applicable Laws with respect to the Product.
5.4 REGULATORY COMPLIANCE. Aventis shall advise Purchaser immediately
if an authorized agent of a Regulatory Authority visits its or its agent's or
designee's manufacturing facilities where the Product is being manufactured or
quality tested. Aventis or its agents or designee's shall furnish to Purchaser
all material information supplied to, or supplied by, any Regulatory Authority,
including the Form 483 observations and responses, to the extent that such
report relates to the Product or the ability of Aventis to supply such Product
within five (5) Business Days of their receipt of such information or delivery
of such information, as the case may be.
5.5 ACCESS TO FACILITIES. Upon the reasonable prior written request of
Purchaser, Purchaser shall have the right during regular business hours to
inspect one (1) time per calendar year those portions of the manufacturing,
storage and testing facilities of Aventis or its designee where Product is being
16
manufactured, stored or tested, as the case may be, to ascertain compliance with
cGMP and the Specifications. If (i) deficiencies are found by Purchaser or any
Regulatory Authority with regard to the Product during the course of such
inspection, (ii) Aventis has failed to deliver the Product in accordance with
Section 2.4 and the circumstances giving rise to such failure relate to the
Aventis facilities referred to in the previous sentence (and/or the inability to
manufacture the Product therein) or (iii) notice has been delivered by Aventis
pursuant to Section 2.6(b) and the circumstances giving rise to such notice
relate to the Aventis facilities referred to in the previous sentence (and/or
the inability to manufacture the Product therein), Purchaser shall be entitled
to perform reasonable follow-up inspections to monitor correction of such
deficiencies or the circumstances giving rise to such failure or notice, as the
case may be.
5.6 PRODUCT INQUIRIES AND COMPLAINTS. Purchaser will promptly submit to
Aventis all Product safety and efficacy inquiries, Product quality complaints
and adverse drug event reports received by it, together with all available
evidence and other information relating thereto, in accordance with procedures
to be agreed upon by the parties pursuant to the Pharmacovigilance Agreement.
Except as otherwise required by law or governmental regulation, Purchaser will
be responsible for investigating and responding to all such inquiries,
complaints and adverse events regarding Product. It shall be the responsibility
of Purchaser to comply with all national, federal, state and local governmental
reporting requirements regarding adverse drug events and Product quality
matters, except where such events or matters are caused by or reasonably
expected to be caused by acts or omissions of Aventis, in which case Purchaser
may, consistent with applicable Law, request the assistance of Aventis in such
compliance.
5.7 RESPONSE TO COMPLAINTS AND/OR ADVERSE DRUG EVENTS. Pursuant to a
reported complaint and/or adverse drug event, if the nature of the reported
complaint and/or adverse drug event requires testing, Aventis will, at
Purchaser's reasonable request and expense, perform analytical testing of
corresponding retention samples and provide the results thereto to Purchaser as
soon as reasonably practicable. Such testing shall be performed using NDA
approved testing procedures as set forth in the applicable NDA.
5.8 ADDITIONAL INFORMATION. Purchaser shall be responsible for assuring
that all promotional material produced by it relating to Products complies with
applicable Laws. Purchaser shall provide to Aventis a copy of each FDA or any
other Regulatory Authority annual report containing information relating to the
Product so long as Purchaser is selling Product utilizing Aventis' packaging.
Such information shall include, without limitation, manufacturing and testing
documentation.
5.9 TECHNICAL AGREEMENT. Each party shall perform the duties required
of it pursuant to a quality and technical agreement to be entered into by the
parties within thirty (30) days of the Effective Date (the "TECHNICAL
AGREEMENT"). To the extent the Technical Agreement either conflicts with this
Agreement or is silent on an issue addressed, this Agreement shall control.
5.10 ANALYTICAL METHOD TRANSFER. Upon the reasonable prior written
request of Purchaser, Aventis agrees to provide Purchaser with all required
documentation and support for analytical method transfer for the Product in
17
order to enable Purchaser to analyze the Product in order to determine its
suitability and stability under this Agreement and according to all applicable
requirements of Regulatory Authorities (a "METHOD Transfer"). Aventis agrees to
actively participate in such Method Transfer by, inter alia, providing samples
and conducting parallel testing up to an aggregate commitment of Aventis
personnel resources to such Method Transfer of one person for two weeks (the
"RESOURCE LIMIT"). In the event that the Aventis resources required for such
Method Transfer exceed the Resource Limit, Purchaser shall pay for such
resources at the then-current daily rate for personnel and laboratory time, as
required. Notwithstanding the foregoing, Purchaser shall pay all reasonable
costs and expenses associated with the travel of Aventis personnel to the site
of any Method Transfer in connection therewith. Anything herein to the contrary
notwithstanding, Aventis shall only be obligated to perform one (1) Method
Transfer pursuant to this Agreement.
ARTICLE 6
PRODUCT RECALLS
6.1 PRODUCT RECALLS. In the event (i) any Regulatory Authority issues a
request, directive or order that Product be recalled, (ii) a court of competent
jurisdiction orders such a recall, or (iii) Purchaser shall reasonably determine
that Product should be recalled, the parties shall take all appropriate
corrective actions, and shall cooperate in the investigations surrounding the
recall. In the event that Purchaser determines that Product should be recalled,
Purchaser shall consult with Aventis prior to taking any corrective actions.
Purchaser shall be responsible for all costs and expenses of any recall
(including, without limitation, any recall initiated as a result of the labeling
of the Product) with respect to Product sold by Purchaser after the Closing
consistent with directions received from the appropriate Regulatory Authority;
PROVIDED, HOWEVER that Aventis shall be responsible for any documented
out-of-pocket costs and expenses in the event, and solely to the extent, that a
recall results from any cause or event arising from the defective manufacture,
testing, storage or handling of the Product by Aventis or its Affiliates or any
of its subcontractors. For purposes of this Agreement, the expenses of recall
shall include the expenses of notification and destruction or return of the
recalled Product and all other documented out-of-pocket costs incurred in
connection with such recall, but shall not, subject to Section 2.12, include
lost profits or opportunity costs of either party. In addition to the foregoing,
it is hereby agreed that in the event, and solely to the extent, that a recall
results from any cause or event arising from the defective manufacture, testing,
storage or handling of the Product by Aventis or its Affiliates, the number of
units of Product subject to such recall shall be deemed units lost in production
solely for purposes of calculating whether the Loss Threshold has been reached.
6.2 DISPUTES. If there is any dispute concerning which party's acts or
omissions gave rise to such recall of Product, such dispute shall be referred
for decision to an independent expert, acting as an expert and not as an
arbitrator, to be mutually agreed upon by Aventis and Purchaser. The decision of
such independent expert shall be in writing and, except for manifest error on
the face of the decision, shall be binding on both Purchaser and Aventis. The
18
costs of such independent expert shall be borne by the party who is found to be
responsible for the recall by the independent expert. After such determination,
costs shall be paid by the responsible party in accordance with Section 6.1.
ARTICLE 7
REPRESENTATIONS, WARRANTIES AND COVENANTS
7.1 AUTHORITY. Each party represents and warrants to the other that it
has the legal power, authority and right to enter into this Agreement and any
other agreements or documents necessary to facilitate the transactions
contemplated hereby ("ADDITIONAL AGREEMENTS") and to carry out the terms and
obligations hereunder and thereunder.
7.2 NO CONFLICTS. Each party represents and warrants to the other that
it is not a party to any agreement or arrangement with any third party or under
any obligation or restriction which in any way limits or conflicts with its
ability to fulfill any of its obligations set forth herein or in the Additional
Agreements.
7.3 COMPLIANCE WITH CGMP. Subject to the New Components supplied to
Aventis complying with all relevant Specifications, Aventis warrants that all
Product has been and will be manufactured in conformity with cGMP and with the
Specifications as defined and approved in the NDA (and any modifications thereto
agreed upon in writing by the Parties).
7.4 CONFORMITY WITH SPECIFICATIONS. Subject to the New Components
supplied to Aventis complying with all relevant Specifications, Aventis warrants
that all Product manufactured by or on behalf of Aventis and sold to Purchaser
pursuant to this Agreement will meet the Specifications at the time of delivery
to the common carrier for such Product in effect at the time of manufacture.
7.5 COMPLIANCE WITH THE ACT. Subject to the New Components supplied to
Aventis complying with all relevant Specifications and other than with regard to
any labeling of any Product to the extent that such labeling has been supplied
by or at the direction of Purchaser and/or its Affiliates and applied in
accordance with instructions from Purchaser, Aventis warrants that all Product
delivered to Purchaser pursuant to this Agreement will, at the time of such
delivery, not be misbranded or adulterated within the meaning of the Act and
will not be an article which may not, under the provisions of such Act, be
introduced into interstate commerce.
7.6 NO LIENS. Aventis warrants that all Product delivered to Purchaser
pursuant to this Agreement will, at the time of such delivery, be free and clear
of all liens, encumbrances, security interests and other encumbrances.
7.7 COMPLIANCE WITH APPLICABLE LAWS. During the Term of this Agreement,
Aventis shall comply in all material respects with all Laws applicable to the
conduct of its business in the performance of this Agreement.
19
7.8 NEW COMPONENTS. Purchaser hereby acknowledges and agrees that it
shall supply, and be responsible for the costs and expenses incurred in
connection with, all New Components to be used in the manufacture of the Product
hereunder, such responsibility to include, without limitation, (i) the
obligation to obtain any new qualification by the FDA or other Regulatory
Authority required in connection with such New Components, (ii) the obtaining of
any other required Regulatory Approvals in connection with such New Components
and (iii) the conduct of stability testing, the running of validation batches
and all other required testing and analysis in connection with such New
Components; PROVIDED, HOWEVER, that Purchaser shall not be responsible for
damage or loss of such New Components occurring in the Product manufacturing
process conducted by, or as a result of the handling of such New Components by,
Aventis any of its Affiliates or any subcontractor. After the Old Components
purchased by Purchaser under the Purchase Agreement are exhausted, in the event
that Aventis cannot supply Product hereunder due to a failure by Purchaser to
subsequently supply New Components therefor for a period equal to or exceeding
twelve (12) months, Aventis shall have the right to terminate this agreement
upon written notice to the Purchaser.
7.9 CFC AVAILABILITY. Anything herein to the contrary notwithstanding,
Aventis shall be relieved of its obligations to supply the Product
(notwithstanding any capacity limits or purchase orders submitted by Purchaser),
and shall not have any obligations (financial or otherwise) or liability
(whether equitable or legal) to Purchaser as a result of a failure to supply the
Product, and Aventis shall not be deemed in breach of this Agreement, if such
failure to supply the Product results from any limitation, modification,
restriction or impairment imposed by any Regulatory Authority on Aventis'
ability to manufacture, supply, export, transfer, handle, store, purchase or
otherwise use or obtain chlorofluorocarbon (a "CFC EVENT"). To the extent that
Aventis can not supply the Product as a result of a CFC Event, then such CFC
Event shall be deemed a Force Majeure and shall be dealt with in accordance with
Section 10.3. During the Term, Aventis shall (i) take such actions with regard
to the procedure for obtaining its allocation of CFC as are consistent with its
past practice and (ii) provide Purchaser with the assistance reasonably
requested by it in order to prevent a CFC Event.
**** In accordance with the terms of Section 7.13, Purchaser shall make
all determinations with regard to, and shall bear all the economic, financial
and other consequences and liabilities of, the accelerated (or non-accelerated)
conversion of such Components in light of the restrictions imposed by the
foregoing sentence.
7.11 RIGHT TO NEW PROCESSES. Aventis hereby agrees to grant to
Purchaser rights which are substantially similar to the rights granted to
Purchaser with respect to the Manufacturing Technology under, and as defined in,
the Product Acquisition Agreement to any new processes actually used and
incorporated in the manufacturing of the Product during the Term.
7.12 HFA AGREEMENT. The parties agree to negotiate in good faith to
enter into an agreement to supply clinical supplies of Triamcinolone Acetonide
hydrofluoroalkane ("HFA") for purposes of obtaining an HFA approval in
connection with the HFA Product.
7.13 SUPPLY COMMITTEE.
20
(a) As promptly as practicable following the Closing Date,
Aventis and Purchaser shall organize a committee charged with oversight of
issues relating to the management of the supplies of Components used in
production of the Product (the "SUPPLY COMMITTEE"). The Supply Committee shall
be composed of three individuals designated by Purchaser in its discretion and
three individuals designated by Aventis in its discretion. The Supply Committee
shall meet at least once per calendar quarter, and may conduct its meetings by
personal meeting, teleconference, video conference or in any other reasonable
manner which allows all persons attending the meeting to communicate effectively
with each other. In the event that the supplier of a Component or a Regulatory
Authority allocating CFC informs either party about a shortage, stoppage,
discontinuance, material price increase or other issue or potential issue that
will or may affect the supply of such Component, Purchaser and Aventis hereby
agree that such matter shall be an issue coming before the Supply Committee,
which shall discuss the steps to be taken (if any) in response to such issue.
(b) Anything herein to the contrary notwithstanding,
Purchaser, with or without consultation with the Supply Committee members
designated by Aventis, shall make all final determinations in its sole and
absolute discretion, consistent with applicable Laws and the terms and
conditions of this Agreement, with regard to the issues addressed by the Supply
Committee or otherwise relating to supplies of Components used in production of
the Product (such issues to include, without limitation, the timing and volume
of conversion of rubber Components to gaskets and gaskets into valves and the
stockpiling of Components). Purchaser hereby acknowledges and agrees that, in so
making such final determinations, it shall be entirely responsible for the
economic and financial consequences thereof, and shall assume and bear all
liabilities of any kind arising in connection therewith, other than any
liabilities of any kind arising as a result of the actions taken by Aventis, its
Affiliates or its subcontractors which are inconsistent with the provisions of
this Section 7.13(b).
(c) Aventis hereby agrees that it shall act in accordance with
each final determination of the Supply Committee as made by Purchaser (so long
as such determination is commercially reasonable with regard to, and shall not
otherwise adversely affect, Aventis), and shall cause its designees on the
Supply Committee to cooperate in a commercially reasonable manner with the
Purchaser designees on the Supply Committee to provide statistical, financial
and other relevant information in Aventis' possession in order to assist
Purchaser in making such determinations; PROVIDED, HOWEVER, that Aventis makes
no, and expressly disclaims any, representations or warranties of any kind with
regard to such information (including, without limitation, any representation or
warranty that such information presents or otherwise captures all of the factors
needed to be taken into account to make any particular determination or achieve
any particular strategy).
7.14 INSURANCE AND TRANSPORT COSTS. Purchaser shall be responsible for,
and shall bear all costs, expenses and other liabilities relating to, the
insurance and transport of all Purchased Components.
7.15 CONSULTING AND QUALIFICATION BY PURCHASER. Aventis shall (i)
reasonably cooperate with Purchaser (such cooperation to include, without
limitation and where reasonably requested by Purchaser and consented to by
21
Aventis (such consent not to be unreasonably withheld, conditioned or delayed),
access from time to time to the appropriate facilities and personnel) in order
to permit Purchaser's personnel to observe and inspect Aventis operations
relating to the Product for purposes of formulating and suggesting production
efficiency improvements and (ii) consider such suggestions in good faith. In
addition, upon the reasonable prior written request of Purchaser and the prior
consent of Aventis (such consent not to be unreasonably withheld, conditioned or
delayed), Aventis may from time to time grant access to Purchaser during regular
business hours to the appropriate Aventis (or Aventis Affiliate) facilities and
personnel (x) for the purpose of furthering the development and/or qualification
of New Components or (y) in connection with other projects mutually pre-approved
by the parties and referenced in the applicable written request for entry.
7.16 EXCLUSION OF OTHER WARRANTIES. EXCEPT WHERE OTHERWISE SET FORTH IN
THIS AGREEMENT, SECTIONS 7.1, 7.2, 7.3, 7.4, 7.5, 7.6 AND 7.7 ARE IN LIEU OF ALL
CONDITIONS, WARRANTIES AND STATEMENTS IN RESPECT OF PRODUCT AND THE SERVICES
PROVIDED HEREUNDER, WHETHER EXPRESSED OR IMPLIED BY STATUTE, CUSTOM OF THE TRADE
OR OTHERWISE, INCLUDING BUT WITHOUT LIMITATION ANY SUCH CONDITION, WARRANTY OR
STATEMENT RELATING TO THE DESCRIPTION OR QUALITY OF PRODUCT, ITS MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE OR USE UNDER ANY CONDITIONS, AND ANY SUCH
CONDITION, WARRANTY OR STATEMENT IS HEREBY EXCLUDED. Except for each Party's
indemnification obligations pursuant to Sections 9.1 and 9.2 for Third Party
Claims, injunctive relief permitted under Section 8.3, and payment obligations
of Aventis pursuant to Section 2.12, in no event shall Aventis or Purchaser
and/or their respective Affiliates, be liable under or with respect to this
Agreement, whether due to breach of warranty, tort, or repudiation of any term
or condition or otherwise, for any indirect, incidental, consequential, special
or punitive damages of any kind, including, but not limited to, loss of profits.
ARTICLE 8
NONDISCLOSURE AND CONFIDENTIALITY
8.1 NONDISCLOSURE OBLIGATIONS.
(a) CONFIDENTIAL AGREEMENT. For the purposes of this
Agreement, the term "Confidential Information" shall mean any and all
information of a party hereto that may be exchanged between the parties at any
time and from time to time before and during the Term in relation to the subject
matter covered by this Agreement. Confidential Information as defined herein
shall in particular be deemed to include, without limitation, all notes,
analyses, compilations, studies, interpretations or other documents, whether in
tangible form or on electronic or other data storage media, prepared by the
receiving party and its Representatives (as defined hereinafter), which contain,
reflect or are based on, in whole or in part, Confidential Information furnished
to the receiving party or its Representatives by the disclosing party or its
Representatives hereunder.
22
(b) DUTIES OF CONFIDENTIALITY AND NON-USE. During the Term,
and for a period of ten (10) years thereafter, each party hereto will maintain
in confidence all Confidential Information disclosed to it by the other party,
and in the case of Aventis, all information relating to the Product, including
without limitation all information and know-how relating to the manufacture of
the Product, which information shall be deemed "Confidential Information" under
this Agreement. Neither party shall use, disclose or grant use of such other
party's Confidential Information except as required in connection with the
performance contemplated under this Agreement. To the extent that disclosure is
necessary to perform this Agreement, the disclosing party shall obtain prior
agreement from its employees, agents, consultants, Affiliates, subcontractors
and sublicensees (collectively, the "REPRESENTATIVES") to whom disclosure is to
be made to hold in confidence and not make use of such information for any
purpose other than those permitted by this Agreement. Each party shall use at
least the same standard of care as it uses to protect its own Confidential
Information to ensure that such Representatives do not disclose or make any
unauthorized use of such Confidential Information. Each party shall promptly
notify the other upon discovery of any unauthorized use or disclosure of
Confidential Information. Confidential Information shall not include any
information which:
(i) was already known to the receiving party, other
than under an obligation of confidentiality, at the time of disclosure by the
other party;
(ii) was generally available to the public or
otherwise part of the public domain at the time of its disclosure to the other
party;
(iii) becomes generally available to the public or
otherwise part of the public domain after its disclosure and other than through
any act or omission of the receiving party in breach of this Agreement;
(iv) was disclosed to the receiving party, other than
under an obligation of confidentiality, by a third party who had no obligation
to the other party not to disclose such information; or
(v) was independently developed by the receiving
party (as evidenced in writing) without reference to the disclosure by the other
party.
(vi) is required by law, regulation, rule, act, or
order of any governmental authority or agency to be disclosed; PROVIDED that the
receiving party gives the disclosing party sufficient notice to permit the
disclosing party to seek a protective order or other similar remedy with respect
to such information and, in the event no such protective order or other remedy
is obtained, the receiving party will furnish only that portion of the
Confidential Information that it is advised by counsel it is legally required to
furnish.
8.2 TERMS OF THIS AGREEMENT. The parties agree not to disclose any
financial terms or conditions of this Agreement to any third party without the
prior consent of the other parties, except as required by applicable Laws.
23
8.3 INJUNCTIVE RELIEF. The parties hereto understand and agree that
remedies at Law may be inadequate to protect against any breach of any of the
provisions of this Article 8 by either party or their employees, agents,
officers or directors or any other person acting in concert with it or on its
behalf. Accordingly, each party may be entitled to the granting of injunctive
relief by a court of competent jurisdiction against any action that constitutes
any such breach of this Article 8.
ARTICLE 9
LIMITATION OF LIABILITY, INDEMNIFICATION AND INSURANCE
9.1 INDEMNIFICATION BY PURCHASER. Except as otherwise specifically
provided herein, Purchaser and Kos Pharmaceuticals, Inc. shall, jointly and
severally, indemnify and hold harmless Aventis, its Affiliates and their
officers, directors, agents or employees against all third party losses, claims,
actions, damages, judgments, liabilities, and expenses, including court costs
and legal fees on a full indemnity basis, or other third party liabilities
("THIRD PARTY LIABILITIES") whatsoever in respect of:
(a) the use, marketing, storage, distribution, handling or
sale of Product after the Effective Date and after title to such Product has
passed to the Purchaser;
(b) any labeling of any Product to the extent that such
labeling has been supplied by or at the direction of Purchaser and/or its
Affiliates and applied in accordance with instructions from Purchaser; and
(c) any representation or warranty made by Purchaser to its
customers or users with respect to Product, other than representations or
warranties contained in Sections 7.1, 7.2, 7.3, 7.4, 7.5, 7.6 and 7.7.
9.2 INDEMNIFICATION BY AVENTIS. Except as otherwise specifically
provided, Aventis and Aventis Pharmaceuticals Holdings Inc. shall, jointly and
severally, indemnify and hold harmless Purchaser, its Affiliates and their
officers, directors, agents or employees against all Third Party Liabilities
whatsoever in respect of:
(a) Aventis' and/or its Affiliates' or their designees'
failure to comply with he Specifications, cGMP, or applicable Laws (other than
with regard to any New Components), and
(b) any breach of a representation or warranty made by Aventis
in Article 7 or elsewhere in this Agreement;
(c) any gross negligence or willful misconduct by Aventis
and/or its Affiliates in the manufacture, testing and handling of Product; and
24
(d) any breach of any agreement or covenant made by Aventis
and/or its Affiliates in this Agreement
9.3 PROCEDURES FOR INDEMNIFICATION.
(a) In the case of a third party claim or demand ("THIRD PARTY
CLAIM") made by any Person who is not a party to this Agreement (or an Affiliate
thereof) as to which a party (the "INDEMNITOR") may be obligated to provide
indemnification pursuant to this Agreement, such party seeking indemnification
hereunder ("INDEMNITEE") will notify the Indemnitor in writing of the Third
Party Claim (and specifying in reasonable detail the factual basis for the Third
Party Claim and to the extent known, the amount of the Third Party Claim)
promptly after becoming aware of such Third Party Claim; PROVIDED, HOWEVER, that
failure to give such notification will not affect the indemnification provided
hereunder except to the extent the Indemnitor shall have been actually
prejudiced as a result of such failure.
(b) If a Third Party Claim is made against an Indemnitee, the
Indemnitor will be entitled, within one hundred twenty (120) days after receipt
of written notice from the Indemnitee of the commencement or assertion of any
such Third Party Claim, to assume the defense thereof (at the expense of the
Indemnitor) with counsel selected by the Indemnitor and reasonably satisfactory
to the Indemnitee, for so long as the Indemnitor is conducting a good faith and
diligent defense. Should the Indemnitor so elect to assume the defense of a
Third Party Claim:
(i) the Indemnitor will not be liable to the
Indemnitee for any legal or other expenses subsequently incurred by the
Indemnitee in connection with the defense thereof; PROVIDED, that if under
applicable standards of professional conduct a conflict of interest exists
between the Indemnitor and the Indemnitee in respect of such claim, such
Indemnitee shall have the right to employ separate counsel (which shall be
reasonably satisfactory to the Indemnitor) to represent such Indemnitee with
respect to the matters as to which a conflict of interest exists and in that
event the reasonable fees and expenses of such separate counsel shall be paid by
such Indemnitor; PROVIDED, FURTHER, that the Indemnitor shall only be
responsible for the reasonable fees and expenses of one separate counsel for
such Indemnitee;
(ii) the Indemnitee shall have the right to
participate in the defense thereof and to employ counsel, at its own expense,
separate from the counsel employed by the Indemnitor;
(iii) the Indemnitor will promptly supply to the
Indemnitee copies of all correspondence and documents relating to or in
connection with such Third Party Claim and keep the Indemnitee informed of
developments relating to or in connection with such Third Party Claim, as may be
reasonably requested by the Indemnitee (including providing to the Indemnitee on
reasonable request updates and summaries as to the status thereof); and
(iv) all Indemnitees shall reasonably cooperate with
the Indemnitor in the defense thereof (such cooperation to be at the expense,
including reasonable legal fees and expenses, of the Indemnitor).
25
(c) If the Indemnitor does not elect to assume control of the
defense of any Third Party Claim within the 120-day period set forth above, or
if such good faith and diligent defense is not being or ceases to be conducted
by the Indemnitor, the Indemnitee shall have the right, at the expense of the
Indemnitor, after three (3) Business Days notice to the Indemnitor of its intent
to do so, to undertake the defense of the Third Party Claim for the account of
the Indemnitor (with counsel selected by the Indemnitee), and to compromise or
settle such Third Party Claim, exercising reasonable business judgment.
(d) If the Indemnitor acknowledges in writing its obligation
to indemnify the Indemnitee for a Third Party Claim, the Indemnitee will agree
to any settlement, compromise or discharge of such Third Party Claim that the
Indemnitor may recommend that by its terms obligates the Indemnitor to pay the
full amount of Third Party Liabilities (whether through settlement or otherwise)
in connection with such Third Party Claim and unconditionally and irrevocably
releases the Indemnitee completely from all Third Party Liabilities in
connection with such Third Party Claim; PROVIDED, HOWEVER, that, without the
Indemnitee's prior written consent, the Indemnitor shall not consent to any
settlement, compromise or discharge (including the consent to entry of any
judgment), and the Indemnitee may refuse to agree to any such settlement,
compromise or discharge, that provides for injunctive or other nonmonetary
relief affecting the Indemnitee. If the Indemnitor acknowledges in writing its
obligation to indemnify the Indemnitee for a Third Party Claim, the Indemnitee
shall not (unless required by Law) admit any liability with respect to, or
settle, compromise or discharge, such Third Party Claim without the Indemnitor's
prior written consent (which consent shall not be unreasonably withheld).
9.4 DISTRIBUTION/ PRODUCT LIABILITY INSURANCE. Purchaser shall obtain
and maintain in effect for the term of this Agreement, liability insurance or
indemnity policies in an amount not less than **** in the aggregate with an
indemnity to principals clause with respect to products liability and
distribution, ****. Such policies shall insure against liability on the part of
Purchaser and any of its Affiliates, as their interests may appear, due to
injury, disability or death of any person or persons, or injury to property,
arising from the manufacturing and/or distribution of Product or Products. Upon
the execution of this Agreement and thereafter on each renewal date of the
insurance policy during the Term, Purchaser shall provide to Aventis a
certificate of insurance (i) summarizing the insurance coverage and (ii)
identifying any exclusions. Purchaser shall promptly notify Aventis of any
material adverse alterations to the terms of this policy or decreases in the
amounts for which insurance is provided.
9.5 PRODUCT LIABILITY CLAIMS. As soon as it becomes aware, each party
will give the other prompt written notice of any defect or alleged defect in a
Product, any injury alleged to have occurred as a result of the use or
application of the Product, and any circumstances that may give rise to
litigation or recall of a Product or regulatory action that may affect the sale
or manufacture of a Product, specifying, to the extent the party has such
information, the time, place and circumstances thereof and the names and
addresses of the persons involved. Each party will also furnish promptly to the
other copies of all papers received in respect of any claim, action or suit
arising out of such alleged defect, injury or regulatory action.
26
ARTICLE 10
GENERAL PROVISIONS
10.1 NOTICES.
(a) Except as otherwise specifically provided, any notice or
other documents to be given under this Agreement shall be in writing and shall
be deemed to have been duly given if sent by registered mail, nationally
recognized overnight courier or facsimile transmission to a party or delivered
in person to a party at the address or facsimile number set out below for such
party or such other address as the party may from time to time designate by
written notice to the other:
If to Purchaser, to: Aeropharm Technology, Inc.
c/o Kos Pharmaceuticals, Inc.
00 Xxxxxxxx Xxxxxx
Xxxxxx, XX 00000
Attn: Xxxxx Xxxxxxx
Vice President, Technical
Operations
Telephone: 000-000-0000
Facsimile: 000-000-0000
with copies to: Kos Pharmaceuticals, Inc.
Raritan Plaza I
000 Xxxxxxxxxx Xxxxxx - 0xx Xxxxx
Xxxxxx, XX 00000
Attn: Xxxxxx X. Xxxxx
Executive Vice President, General
Counsel and Corporate Secretary
Telephone: 000-000-0000
Facsimile: 732-225-8901
and
Kos Pharmaceuticals, Inc.
0000 Xxxxxxxx Xxx Xxxxx
00xx Xxxxx
Xxxxx, XX 00000
Attn: Xxxx Xxxxxxxxx,
Vice President and Controller
Telephone: 000-000-0000
Facsimile: 000-000-0000
27
If to Aventis to: Aventis Pharmaceuticals Inc.
000 Xxxxxxxx Xxxx.
Mail Stop BX2-709D
Xxxxxxxxxxx, XX 00000-0000
Attn: North American Supply
Chain Leader
Facsimile: 000-000-0000
with a copy to: Aventis Pharmaceuticals Inc.
000 Xxxxxxxx Xxxx. Xxxx.
Mail Stop SC3-820A
Xxxxxxxxxxx, XX 00000-0000
Attn: General Counsel
Facsimile: 000-000-0000
(b) Any such notice or other document shall be deemed to have
been received by the addressee five (5) Business Days following the date of
dispatch of the notice or other document by mail or, where the notice or other
document is sent by overnight courier, by hand or is given by facsimile,
simultaneously with the transmission or delivery. To prove the giving of a
notice or other document it shall be sufficient to show that it was dispatched.
10.2 ENTIRE AGREEMENT; AMENDMENT.
(a) This Agreement (including all exhibits and schedules
hereto), together with the other Transaction Agreements (as defined in the
Product Acquisition Agreement), embodies and sets forth the entire agreement and
understanding of the parties with respect to the subject matter herein and there
are no promises, terms, conditions or obligations, oral or written, expressed or
implied, other than those contained in this Agreement and the Transaction
Agreements. The terms of this Agreement and the other Transaction Agreements
shall supersede all previous oral or written agreements which may exist or have
existed between the parties relating to the subject matter of this Agreement and
the other Transaction Agreements. No party shall be entitled to rely on any
agreement, understanding or arrangement which is not expressly set forth in this
Agreement and the other Transaction Agreements. Any other terms and conditions,
including without limitation any terms and conditions contained in any purchase
order or sales invoice issued pursuant to this Agreement and the other
Transaction Agreements, are hereby expressly excluded.
(b) This Agreement shall not be amended, modified, varied or
supplemented except in writing signed by duly authorized representatives of the
parties.
10.3 FORCE MAJEURE. If a party is prevented or delayed in the
performance of any of its obligations under this Agreement by Force Majeure and
shall give written notice thereof to the other parties specifying the matters
constituting Force Majeure together with such evidence as such party reasonably
can give and specifying the period for which it is estimated that such
prevention or delay will continue, the party shall be excused from the
28
performance or the punctual performance of such obligations as the case may be
from the date of such notice for so long as such cause of prevention or delay
shall continue. The expression "FORCE MAJEURE" shall be deemed to include any
cause substantially affecting the performance by a party of this Agreement
arising from or attributable to acts, events, non-happenings, omissions or
accidents beyond the reasonable control of the party whose performance is so
affected. ****
10.4 ASSIGNMENT. Aventis shall not be entitled to assign its rights and
obligations hereunder without the prior written consent of Purchaser; PROVIDED,
HOWEVER, that Aventis shall be entitled, without the prior written consent of
Purchaser, to assign its rights and obligations hereunder (i) to an Affiliate,
but such assignment to such Affiliate shall not relieve Aventis of any of its
obligations hereunder, or (ii) in connection with a sale or assignment of all or
substantially all of the assets used in the manufacture of the Product.
Purchaser shall not be entitled to assign its rights and obligations hereunder
without the prior written consent of Aventis; PROVIDED, HOWEVER, that Purchaser
shall be entitled, without the prior written consent of Aventis, to assign its
rights and obligations hereunder (i) to an Affiliate, but such assignment to
such Affiliate shall not relieve Purchaser of any of its obligations hereunder,
or (ii) in connection with a sale or assignment of all or substantially all of
the assets relating to the Product. No permitted assignment hereunder shall be
deemed effective until the assignee shall have executed and delivered an
instrument in writing reasonably satisfactory in form and substance to the other
party pursuant to which the assignee assumes all of the obligations of assigning
party hereunder. Any purported assignment of this Agreement in violation of this
Section 10.4 shall be void. This Agreement shall be binding upon the successors
and permitted assigns of the parties and the name of a party shall be deemed to
include the names of its successors and assigns.
10.5 HEADINGS, INTERPRETATION. The headings used in this Agreement are
for convenience only and are not a part of this Agreement nor affect the
interpretation of any of its provisions.
10.6 INDEPENDENT PARTIES. This Agreement shall not be deemed to create
any partnership, joint venture, amalgamation or agency relationship between
Aventis and Purchaser. Each party shall act hereunder as an independent
contractor.
10.7 GOVERNING LAW. This Agreement shall be governed by and construed
under the laws of the State of New York, without giving effect to the choice of
law provisions thereof.
10.8 NO WAIVER. Neither the failure nor delay on the part of a party to
require the strict performance of any term, covenant or condition of this
Agreement or to exercise any right or remedy available on a breach thereof shall
constitute a waiver of any such breach or of any such term or condition. The
consent to, or the waiver of, any breach, or the failure to require on any
single occasion the performance or timely performance of any term, covenant, or
29
condition of this Agreement shall be in writing and shall not be construed as
authorizing any subsequent or additional breach and shall not prevent a
subsequent enforcement of such term, covenant, or condition.
10.9 SEVERABILITY. In the event that any provision of this Agreement or
the application thereof to any party or circumstance shall be finally determined
by a court of proper jurisdiction to be invalid or unenforceable to any extent,
then (i) a suitable and equitable provision shall be substituted therefore in
order to carry out, so far as may be valid and enforceable, the intent and
purpose of such invalid and unenforceable provision and (ii) the remainder of
this Agreement and the application of such provision to the parties or
circumstances other than those to which it is held invalid or unenforceable
shall not be affected thereby.
10.10 INTERPRETATION. The parties hereto acknowledge and agree that:
(i) each party and its representatives has reviewed and negotiated the terms and
provisions of this Agreement and have contributed to its revision; (ii) the rule
of construction to the effect that any ambiguities are resolved against the
drafting party shall not be employed in the interpretation of this Agreement;
and (iii) the terms and provisions of this Agreement shall be construed fairly
as to each party hereto and not in favor of or against either party regardless
of which party was generally responsible for the preparation of this Agreement.
10.11 COUNTERPARTS. This Agreement may be executed simultaneously in
two or more counterparts (and may be delivered by facsimile), each of which
shall be deemed an original, but all of which together shall constitute a single
agreement.
10.12 THIRD PARTY BENEFICIARIES. This Agreement is not intended to
confer upon any non-party rights or remedies hereunder, except as may be
received or created as part of a valid permitted assignment.
10.13 FURTHER ASSURANCES. Each party shall execute and deliver such
additional instruments and other documents and use commercially reasonable
efforts to take or cause to be taken, all actions and to do, or cause to be
done, all things necessary under applicable law to consummate the transactions
contemplated hereby.
10.14 USE OF AFFILIATES. The rights and obligations of the parties set
forth in this Agreement include the right of each party to use its Affiliates in
exercising such rights and carrying out its obligations under this Agreement;
PROVIDED that in the event any such Affiliate ceases to meet the definition of
an Affiliate, whether due to the transfer or sale of all or substantially all of
the assets or stock of such Affiliate or otherwise, then such right with respect
to such Affiliate shall terminate; and PROVIDED, FURTHER, the parties to this
Agreement shall remain fully liable for the performance of the terms of this
Agreement notwithstanding any assignment to or performance by such Affiliate.
SIGNATURE PAGE FOLLOWS
30
IN WITNESS WHEREOF, the parties hereto have each caused this Agreement
to be duly executed as of the Effective Date.
AVENTIS:
AVENTIS PHARMACEUTICALS INC.
By: /s/
-------------------------------------
Name:
Title:
PURCHASER:
AEROPHARM TECHNOLOGY, INC.
By: /s/
-------------------------------------
Name:
Title:
ACCEPTED AND AGREED
Solely for purposes of
Sections 9.1 and 9.3 and Article X hereof:
KOS PHARMACEUTICALS, INC.
By: /s/
-------------------------------
Name:
Title:
ACCEPTED AND AGREED
Solely for purposes of
Sections 9.2 and 9.3 and Article X hereof:
AVENTIS PHARMACEUTICALS HOLDINGS INC.
By: /s/
-------------------------------
Name:
Title:
31
